Literature DB >> 10500291

The moving target: mechanisms of HIV persistence during primary infection.

H Soudeyns1, G Pantaleo.   

Abstract

The vigorous host immune responses detected during primary HIV infection fail to prevent the establishment of chronic infection because HIV has evolved multiple strategies to make these responses ineffective. Here, Hugo Soudeyns and Giuseppe Pantaleo discuss the mechanisms that allow HIV to persist in the host.

Entities:  

Mesh：

Year:  1999        PMID： 10500291     DOI： 10.1016/s0167-5699(99)01504-2

Source DB:  PubMed          Journal:  Immunol Today        ISSN： 0167-5699


  16 in total

1.  DNA vaccines expressing different forms of simian immunodeficiency virus antigens decrease viremia upon SIVmac251 challenge.

Authors:  Margherita Rosati; Agneta von Gegerfelt; Patricia Roth; Candido Alicea; Antonio Valentin; Marjorie Robert-Guroff; David Venzon; David C Montefiori; Phil Markham; Barbara K Felber; George N Pavlakis
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

Review 2.  Polyvalent AIDS vaccines.

Authors:  Shan Lu; Jill M Grimes Serrano; Shixia Wang
Journal:  Curr HIV Res       Date:  2010-12       Impact factor: 1.581

3.  Binding of LFA-1 (CD11a) to intercellular adhesion molecule 3 (ICAM-3; CD50) and ICAM-2 (CD102) triggers transmigration of human immunodeficiency virus type 1-infected monocytes through mucosal epithelial cells.

Authors:  Marie-Paule Carreno; Nicolas Chomont; Michel D Kazatchkine; Theano Irinopoulou; Corrine Krief; Ali-Si Mohamed; Laurent Andreoletti; Mathieu Matta; Laurent Belec
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

4.  Immune activation in the pathogenesis of treated chronic HIV disease: a workshop summary.

Authors:  Susan F Plaeger; Brenda S Collins; Runa Musib; Steven G Deeks; Sarah Read; Alan Embry
Journal:  AIDS Res Hum Retroviruses       Date:  2011-09-27       Impact factor: 2.205

5.  Flow cytometry evaluation of the T-cell receptor Vbeta repertoire among HIV-1 infected individuals before and after antiretroviral therapy.

Authors:  Carmem Beatriz Wagner Giacoia-Gripp; Ivan Neves; Maria Clara Galhardo; Mariza Gonçalves Morgado
Journal:  J Clin Immunol       Date:  2005-03       Impact factor: 8.317

6.  Polyvalent DNA prime and envelope protein boost HIV-1 vaccine elicits humoral and cellular responses and controls plasma viremia in rhesus macaques following rectal challenge with an R5 SHIV isolate.

Authors:  Ranajit Pal; Shixia Wang; V S Kalyanaraman; B C Nair; Stephen Whitney; Timothy Keen; Lindsey Hocker; Lauren Hudacik; Nicolas Rose; Anthony Cristillo; Innocent Mboudjeka; Siyuan Shen; Te-Hui Wu-Chou; David Montefiori; John Mascola; Shan Lu; Phillip Markham
Journal:  J Med Primatol       Date:  2005-10       Impact factor: 0.667

7.  Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy.

Authors:  G Paolo Rizzardi; Alexandre Harari; Brunella Capiluppi; Giuseppe Tambussi; Kim Ellefsen; Donatella Ciuffreda; Patrick Champagne; Pierre-Alexandre Bart; Jean-Philippe Chave; Adriano Lazzarin; Giuseppe Pantaleo
Journal:  J Clin Invest       Date:  2002-03       Impact factor: 14.808

8.  Evolution of HIV-1 coreceptor usage and coreceptor switching during pregnancy.

Authors:  Doris G Ransy; Alena Motorina; Natacha Merindol; Bertine S Akouamba; Johanne Samson; Yolanda Lie; Laura A Napolitano; Normand Lapointe; Marc Boucher; Hugo Soudeyns
Journal:  AIDS Res Hum Retroviruses       Date:  2013-10-25       Impact factor: 2.205

9.  A balanced type 1/type 2 response is associated with long-term nonprogressive human immunodeficiency virus type 1 infection.

Authors:  Nesrina Imami; Antonio Pires; Gareth Hardy; Jamie Wilson; Brian Gazzard; Frances Gotch
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

Review 10.  Catalytic antibodies to HIV: physiological role and potential clinical utility.

Authors:  Stephanie Planque; Yasuhiro Nishiyama; Hiroaki Taguchi; Maria Salas; Carl Hanson; Sudhir Paul
Journal:  Autoimmun Rev       Date:  2008-04-29       Impact factor: 9.754
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.